KR20230093429A - 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법 - Google Patents

알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법 Download PDF

Info

Publication number
KR20230093429A
KR20230093429A KR1020237013278A KR20237013278A KR20230093429A KR 20230093429 A KR20230093429 A KR 20230093429A KR 1020237013278 A KR1020237013278 A KR 1020237013278A KR 20237013278 A KR20237013278 A KR 20237013278A KR 20230093429 A KR20230093429 A KR 20230093429A
Authority
KR
South Korea
Prior art keywords
compound
egfr
leu
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237013278A
Other languages
English (en)
Korean (ko)
Inventor
엘리자베스 벅
매튜 오코노
달린 로마시코
타이-안 린
알렉산더 플로르
루카 아리스타
이보나 브로나
매튜 루카스
크리스 로버츠
조르지오 오타비아니
셰리 스미스
니겔 워터스
Original Assignee
블랙 다이아몬드 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 filed Critical 블랙 다이아몬드 테라퓨틱스, 인코포레이티드
Publication of KR20230093429A publication Critical patent/KR20230093429A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237013278A 2020-11-02 2021-11-02 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법 Pending KR20230093429A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063108645P 2020-11-02 2020-11-02
US63/108,645 2020-11-02
US202163166045P 2021-03-25 2021-03-25
US63/166,045 2021-03-25
US202163190067P 2021-05-18 2021-05-18
US63/190,067 2021-05-18
US202163218717P 2021-07-06 2021-07-06
US63/218,717 2021-07-06
US202163237782P 2021-08-27 2021-08-27
US63/237,782 2021-08-27
US202163244540P 2021-09-15 2021-09-15
US63/244,540 2021-09-15
PCT/US2021/057724 WO2022094464A1 (en) 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives

Publications (1)

Publication Number Publication Date
KR20230093429A true KR20230093429A (ko) 2023-06-27

Family

ID=78819639

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013278A Pending KR20230093429A (ko) 2020-11-02 2021-11-02 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법

Country Status (10)

Country Link
US (1) US20240075042A1 (https=)
EP (1) EP4236954A1 (https=)
JP (1) JP2023548055A (https=)
KR (1) KR20230093429A (https=)
AU (1) AU2021368798A1 (https=)
CA (1) CA3195473A1 (https=)
IL (1) IL302329A (https=)
MX (1) MX2023004998A (https=)
TW (1) TWI910256B (https=)
WO (1) WO2022094464A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CA3231697A1 (en) * 2021-09-21 2023-03-30 Black Diamond Therapeutics, Inc. Polymorphs as erbb inhibitors
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
WO2025128831A1 (en) * 2023-12-13 2025-06-19 Black Diamond Therapeutics, Inc. Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122058A2 (en) * 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
JP2022502495A (ja) * 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
AU2020328598A1 (en) * 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Also Published As

Publication number Publication date
TWI910256B (zh) 2026-01-01
IL302329A (en) 2023-06-01
AU2021368798A9 (en) 2023-07-06
MX2023004998A (es) 2023-05-12
EP4236954A1 (en) 2023-09-06
WO2022094464A1 (en) 2022-05-05
US20240075042A1 (en) 2024-03-07
CA3195473A1 (en) 2022-05-05
JP2023548055A (ja) 2023-11-15
AU2021368798A1 (en) 2023-05-18
TW202235083A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
KR20230093429A (ko) 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법
KR102857219B1 (ko) 암의 치료 또는 예방용 의약
JP5778735B2 (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
CA2943834A1 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US9295676B2 (en) Mutation mimicking compounds that bind to the kinase domain of EGFR
KR20220079903A (ko) 조절이상 섬유모세포 성장 인자 수용체 신호전달을 갖는 암의 표적화 치료
CN113164776A (zh) 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
WO2025038731A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
CN116710096A (zh) 用炔取代的喹唑啉衍生物治疗癌症的方法
US20230321087A1 (en) Fgfr inhibitor combination therapies
KR20260053328A (ko) 알킨 치환된 퀴나졸린 유도체를 이용한 암 치료 방법
CN111000982A (zh) Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途
EP4534085A1 (en) Compounds for use in methods of treating cancer
WO2026064728A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
Mettu et al. How I Treat Metastatic Colorectal Cancer With Emerging Therapeutic Strategies
CN121941699A (zh) 表皮生长因子受体抑制剂
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease
EA051616B1 (ru) Лечение рака

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000